Skip to main content

Advertisement

SpringerLink
Log in

Anticancer Drug Therapy in the Older Cancer Patient: Pharmacology and Polypharmacy

  • Geriatric Oncology
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Older patients currently are the largest group of oncology patients and their numbers will continue to expand. There has been minimal participation of older patients in clinical trials. This has resulted in a lack of data to make high-level evidence-based decisions with regard to chemotherapy. There has now been a number of clinical trials which have given information with regard to age-related changes and the spectrum of toxicity that occurs with older patients. There is also an expanding literature on organ dysfunction. The overall data seem to indicate that there are a very few age-related changes in the pharmacokinetics of chemotherapy. The small changes that are present have not been clinically significant. It seems that the pattern of toxicity is more reflective of patient selection (functional status, performance status), comorbidity, and drug scheduling. The large number of drugs with significant renal excretion requires careful evaluation of renal function. Future clinical trial design needs to be adapted to older patients. Therefore, drugs, which will be primarily used by older patients, should be studied in older patients. These studies should involve pharmacokinetics, and oral therapies should include measurements of compliance. Phase II trials of new agents should consider prospectively dividing groups of patients by age (i.e., <75 years vs. ≥ 5 years). Phase I trials should consider accruing older patients. The studies can be performed in the older group by using progressive degrees of functional impairment and increasing comorbidity as a surrogate for dose limiting toxicity. Functional independence as a clinical benefit of cancer treatment in older individuals should be considered as an endpoint. Overall survival may not be an appropriate endpoint in clinical trials in the oldest group. Clinical trials should consider studying long-term functional and medical consequences of cancer treatment in long-term older cancer survivors. Journal editors should encourage the inclusion of age-related analyses in the reporting of clinical trials to provide meaningful information for clinicians caring for older patients. Ideally, the clinical trial design should prospectively incorporate age analysis to maximize clinical benefit of data generated. A careful assessment of medication used in older patients needs to be part of routine evaluation to minimize the adverse effects of polypharmacy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Venook AP, Egorin MJ, Rosner GL, et al.: Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol 2000, 18:2780–2787

    CAS  PubMed  Google Scholar 

  2. Venook AP, Enders Klein C, Fleming G, et al.: A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann Oncol 2003;14:1783–1790, doi:10.1093/annonc/mdg493

    Article  CAS  PubMed  Google Scholar 

  3. Smith TJ, Khatcheressian J, Lyman GH, et al.: 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187–3205

    Article  CAS  PubMed  Google Scholar 

  4. Launay-Vacher V, Oudard S, Janus N, et al.: Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer 2007;110:1376–1384, doi:10.1002/cncr.22904

    Article  CAS  PubMed  Google Scholar 

Evaluation of renal function in the elderly is essential for the safe administration of chemotherapy. Serum creatinines are not adequate for assessment.

  1. Lichtman SM, Wildiers H, Launay-Vacher V, et al.: International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 2007;43:14–34

    Article  PubMed  Google Scholar 

  2. Launay-Vacher V, Chatelut E, Lichtman S, et al.: Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. Ann Oncol, 2007, 18, 1314–1321

    Article  CAS  PubMed  Google Scholar 

  3. National Comprehensive Cancer Network: Senior Adult Oncology. 2007, www.nccn.org accessed March 29, 2008

  4. Vigneau C, Ardiet C, Bret M, et al.: Intermediate-dose (25 mg/m2) IV melphalan for multiple myeloma with renal failure. J Nephrol 2002;15:684–689

    CAS  PubMed  Google Scholar 

  5. Jantunen E, Kuittinen T, Penttila K, et al.: High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (>or=65 years) myeloma patients: comparison with younger patients treated on the same protocol. Bone Marrow Transplant 2006;37:917–922

    Article  CAS  PubMed  Google Scholar 

  6. Stein BN, Petrelli NJ, Douglass HO, et al.: Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer 1995;75:11–17

    Article  CAS  PubMed  Google Scholar 

  7. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer. J Clin Oncol 16:3537–3541, 1998

  8. Sargent DJ, Goldberg RM, Jacobson SD, et al.: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001;345:1091–1097

    Article  CAS  PubMed  Google Scholar 

This large metaanalysis showed that older patients can benefit from adjuvant therapy with acceptable toxicity. One of the large analyses of data specifically for older patients.

  1. Goldberg RM, Tabah-Fisch I, Bleiberg H, et al.: Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006;24:4085–4091

    Article  CAS  PubMed  Google Scholar 

  2. Haller DG, Catalano PJ, Macdonald JS, et al.: Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage ii and iii colon cancer: final report of Intergroup 0089. J Clin Oncol 23:8671–8678, 2005

    Article  PubMed  Google Scholar 

  3. Schrag D, Cramer LD, Bach PB, et al.: Age and adjuvant chemotherapy use after surgery for stage iii colon cancer. J Natl Cancer Inst 2001;93:850–857

    Article  CAS  PubMed  Google Scholar 

  4. Folprecht G, Cunningham D, Ross P, et al.: Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol 2004;15:1330–1338

    Article  CAS  PubMed  Google Scholar 

  5. Cassidy J, Twelves C, Cameron D, et al.: Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients. Cancer Chemother Pharmacol 1999;44:453–460

    Article  CAS  PubMed  Google Scholar 

  6. Twelves C, Wong A, Nowacki MP, et al.: Capecitabine as adjuvant treatment for stage iii colon cancer. N Engl J Med 2005;352:2696–2704

    Article  CAS  PubMed  Google Scholar 

  7. Feliu J, Escudero P, Llosa F, et al.: Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study. J Clin Oncol 2005;23:3104–3111

    Article  CAS  PubMed  Google Scholar 

  8. Takimoto CH, Remick SC, Sharma S, et al.: Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. J Clin Oncol 2003;21:2664–2672

    Article  CAS  PubMed  Google Scholar 

  9. Aparicio T, Desrame J, Lecomte T, et al.: Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly. Br J Cancer 2003;89:1439–1444

    Article  CAS  PubMed  Google Scholar 

  10. Feliu J, Salud A, Escudero P, et al.: XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer 2006;94:969–975

    Article  CAS  PubMed  Google Scholar 

  11. Langer CJ, Manola J, Bernardo P, et al.: Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of eastern cooperative oncology group 5592, a randomized trial. J Natl Cancer Inst 2002;94:173–181

    PubMed  Google Scholar 

  12. Calvert AH, Egorin MJ: Carboplatin dosing formulae: gender bias and the use of creatinine-based methodologies. Eur J Cancer 2002;38:11–16

    Article  CAS  PubMed  Google Scholar 

  13. Swain SM, Whaley FS, Ewer MS: Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003;97:2869–2879

    Article  CAS  PubMed  Google Scholar 

  14. Dees EC, O’Reilly S, Goodman SN, et al.: A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Invest 2000;18:521–529

    Article  CAS  PubMed  Google Scholar 

  15. Safra T, Muggia F, Jeffers S, et al.: Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol 2000;11:1029–1033

    Article  CAS  PubMed  Google Scholar 

  16. Tannock IF, de Wit R, Berry WR, et al.: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502–1512

    Article  CAS  PubMed  Google Scholar 

  17. Wong M, Balleine RL, Blair EY, et al.: Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer. J Clin Oncol 2006;24:2448–2455

    Article  CAS  PubMed  Google Scholar 

  18. Lichtman SM, Hollis D, Miller AA, et al.: Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762). J Clin Oncol 2006;24:1846–1851

    Article  CAS  PubMed  Google Scholar 

Largest prospective trial of the pharmacology of chemotherapy in older patients. Demonstrated that these trials are feasible.

  1. Smorenburg CH, ten Tije AJ, Verweij J, et al.: Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer. Eur J Cancer 2003;39:196–202

    Article  CAS  PubMed  Google Scholar 

  2. Seidman AD, Berry D, Cirrincione C, et al.: Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008;26:1642–1649

    Article  CAS  PubMed  Google Scholar 

  3. Hurria A, Fleming MT, Baker SD, et al.: Pharmacokinetics and toxicity of weekly docetaxel in older patients. Clin Cancer Res 2006;12:6100–6105

    Article  CAS  PubMed  Google Scholar 

  4. Lichtman SM, Etcubanas E, Budman DR, et al.: The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: a prospective dose adjustment study. Cancer Invest 2002;20:904–913

    Article  CAS  PubMed  Google Scholar 

  5. Martell RE, Peterson BL, Cohen HJ, et al.: Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study. Cancer Chemother Pharmacol 2002;50:37–45

    Article  CAS  PubMed  Google Scholar 

  6. Launay-Vacher V, Karie S, Deray G: GPR® Anticancéreux. Guide de prescription des médicaments chez le patient insuffisant renal (ed 3ème). Paris, Méditions International, 2005

  7. Mita AC, Sweeney CJ, Baker SD, et al.: Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol 2006;24:552–562

    Article  CAS  PubMed  Google Scholar 

  8. Weiss GJ, Langer C, Rosell R, et al.: Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2006;24:4405–4411

    Article  CAS  PubMed  Google Scholar 

  9. O’Reilly S, Armstrong DK, Grochow LB: Life-threatening myelosuppression in patients with occult renal impairment receiving topotecan [letter]. Gynecol Oncol 1997;67:329–330

    Article  PubMed  Google Scholar 

  10. Armstrong DK: Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity. Oncologist 2004;9:33–42

    Article  CAS  PubMed  Google Scholar 

  11. Fuchs CS, Moore MR, Harker G, et al.: Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 2003;21:807–814

    Article  CAS  PubMed  Google Scholar 

  12. Miller AA, Rosner GL, Ratain MJ, et al.: Pharmacology of 21-day oral etoposide given in combination with i.v. Cisplatin in patients with extensive-stage small cell lung cancer: A Cancer and Leukemia Group B study (CALGB 9062). Clin Cancer Res 1997;3:719–725

    CAS  PubMed  Google Scholar 

  13. Tan-Chiu E, Yothers G, Romond E, et al.: Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23:7811–7819

    Article  CAS  PubMed  Google Scholar 

  14. Scappaticci FA, Skillings JR, Holden SN, et al.: Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007;99:1232–1239

    Article  PubMed  Google Scholar 

  15. Jackman DM, Yeap BY, Lindeman NI, et al.: Phase II clinical trial of chemotherapy-naive patients >or= 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007;25:760–766

    Article  CAS  PubMed  Google Scholar 

  16. Fulton MM, Allen ER: Polypharmacy in the elderly: a literature review. J Am Acad Nurse Pract 2005;17:123–132

    Article  PubMed  Google Scholar 

  17. Bergman-Evans B: AIDES to improving medication adherence in older adults. Geriatr Nurs 2006;27:174–282; quiz 183

    Google Scholar 

  18. Burkhart PV, Sabate E: Adherence to long-term therapies: evidence for action. J Nurs Scholarsh 2003;35:207

    PubMed  Google Scholar 

  19. Partridge AH, Avorn J, Wang PS, et al.: Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 2002;94:652–661

    PubMed  Google Scholar 

  20. Cutting Edge Information: http://www.cuttingedgeinfo.com/pharmapatientadherence/, accessed April 29, 2008

  21. Tsang J, Rudychev I, Pescatore SL: Prescription compliance and persistency in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients (pts) on imatinib (IM) [meeting abstracts]. J Clin oncol 2006, 24(Suppl 18):6119

    Google Scholar 

  22. Partridge AH, LaFountain A, Mayer E, et al.: Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 2008;26:556–562

    Article  CAS  PubMed  Google Scholar 

  23. Osterberg L, Blaschke T: Adherence to medication. N Engl J Med 2005;353:487–497

    Article  CAS  PubMed  Google Scholar 

  24. Pugh MJ, Hanlon JT, Zeber JE, et al.: Assessing potentially inappropriate prescribing in the elderly Veterans Affairs population using the HEDIS 2006 quality measure. J Manag Care Pharm 2006;12:537–545

    PubMed  Google Scholar 

  25. Hartigan K: Patient education: the cornerstone of successful oral chemotherapy treatment. Clin J Oncol Nurs 2003;7:21–24

    Article  PubMed  Google Scholar 

  26. Beers MH: Explicit criteria for determining potentially inappropriate medication use by the elderly. An update. Arch Intern Med 1997;157:1531–1536

    Article  CAS  PubMed  Google Scholar 

  27. Fick DM, Cooper JW, Wade WE, et al.: Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003;163:2716–2724

    Article  PubMed  Google Scholar 

  28. Barry PJ, O’Keefe N, O’Connor KA, et al.: Inappropriate prescribing in the elderly: a comparison of the Beers criteria and the improved prescribing in the elderly tool (IPET) in acutely ill elderly hospitalized patients. J Clin Pharm Ther 2006;31:617–626

    Article  CAS  PubMed  Google Scholar 

  29. Cannon KT, Choi MM, Zuniga MA: Potentially inappropriate medication use in elderly patients receiving home health care: a retrospective data analysis. Am J Geriatr Pharmacother 2006;4:134–143

    Article  PubMed  Google Scholar 

  30. Budnitz DS, Shehab N, Kegler SR, et al.: Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med 2007;147:755–765

    PubMed  Google Scholar 

  31. Lichtman SM: Chemotherapy in the elderly. Semin Oncol 2004;31:160–174

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Stuart M. Lichtman MD & Manpreet K. Boparai PharmD

  2. Memorial Sloan Kettering Cancer Center, Commack, NY, 11725, USA

    Stuart M. Lichtman MD

Authors
  1. Stuart M. Lichtman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Manpreet K. Boparai PharmD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stuart M. Lichtman MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lichtman, S.M., Boparai, M.K. Anticancer Drug Therapy in the Older Cancer Patient: Pharmacology and Polypharmacy. Curr. Treat. Options in Oncol. 9, 191–203 (2008). https://doi.org/10.1007/s11864-008-0060-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-008-0060-6

Keywords

Search

Navigation